Focus: Tonix is a public CNS-focused pharmaceutical company with 5,000+ employees developing novel treatments for neurology disorders including fibromyalgia and PTSD. The company maintains a portfolio of generic and branded assets alongside an active clinical pipeline.
Profile data last refreshed 4h ago · AI intelligence enriched 1mo ago
Stable — net -1 jobs in 30d
8 added, 9 removed. Backfill posture.
Tonix is a high-risk, high-reward opportunity for biotech professionals seeking pipeline exposure in CNS with meaningful near-term financial pressure and limited margin for execution error.
Multiple generic ANDA filings for cyclobenzaprine; post-LOE status indicates commodity market positioning with limited differentiation.
Help build intelligence for Tonix Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tonix Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Post-LOE generic formulation contributing to commodity revenue base with declining margins.
Additional post-LOE cyclobenzaprine ANDA with limited growth potential in saturated generic market.
Post-LOE generic cyclobenzaprine contributing to baseline revenue but facing competitive generic erosion.
Generic muscle relaxant ANDA filing in mature market segment with limited upside.
Post-LOE generic cyclobenzaprine with commodity pricing dynamics limiting growth.
Additional generic cyclobenzaprine ANDA facing mature market competition.
Branded cyclobenzaprine formulation recently secured Medicare PBM coverage for 145M lives (July 2026); key near-term commercial catalyst with 8+ year LOE runway.
Post-LOE generic cyclobenzaprine ANDA in saturated competitive market.
symbol__ Stock Quote Price and Forecast - cnn.com
symbol__ Stock Quote Price and Forecast cnn.com
Tonix Pharmaceuticals Holding Corp. (TNXP) Peer Comparison – Compare with Others - Value Research
Tonix Pharmaceuticals Holding Corp. (TNXP) Peer Comparison – Compare with Others Value Research
AQR Capital discloses 5.54% ownership in Tonix Pharmaceuticals (TNXP) via Schedule 13G - Stock Titan
AQR Capital discloses 5.54% ownership in Tonix Pharmaceuticals (TNXP) via Schedule 13G Stock Titan
Tonix Pharmaceuticals Q2 Earnings Call Highlights - TradingView
Tonix Pharmaceuticals Q2 Earnings Call Highlights TradingView
Tonix Pharmaceuticals (TNXP) Earnings Date and Reports 2026 - MarketBeat
Tonix Pharmaceuticals (TNXP) Earnings Date and Reports 2026 MarketBeat
Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S. - GlobeNewswire
Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S. GlobeNewswire
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo